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Background: Angiotensin 1 converting enzyme (ACE) inhibitors reduce morbidity and mortality after
coronary artery bypass graft surgery (CABG). This benefit may result from an anti-inflammatory action.
Objective: To examine the effect of ACE inhibition on interleukin 6 (IL-6) concentrations after CABG.
Patients and methods: 161 patients undergoing elective first time CABG were recruited, of whom 41
(25%) were receiving ACE inhibitor treatment; 21 patients with confounding postoperative complica-
tions were excluded. After these exclusions there were 33 patients (24%) on ACE inhibitor treatment.
Plasma IL-6 was measured preoperatively and again six hours after CABG.
Results: Baseline IL-6 concentrations (geometric mean (SEM)) were non-significantly lower among the
patients receiving ACE inhibitors (3.7 (0.1) v 4.3 (0.1) pg/ml, p = 0.12). Overall, post-CABG IL-6
concentrations increased significantly (mean rise 177 (12) pg/ml, p < 0.0005). This response was
blunted among ACE inhibitor treated patients. Median increases in IL-6 concentrations were 117 v
193 pg/ml, for treated v non-treated patients, respectively (Kruskal–Wallis, p = 0.02), with peak post-
operative IL-6 concentrations lower among the subjects receiving ACE inhibitors than in untreated
subjects (142 (19) v 196 (13) pg/ml, p = 0.02). The effect of ACE inhibitors remained significant after
multivariate analysis (p = 0.018).
Conclusions: ACE inhibitor treatment is associated with a reduction in IL-6 response to CABG. The
data suggest that this class of drug may have a direct anti-inflammatory effect, which could explain
some of its clinical benefit.
Treatment with angiotensin 1 converting enzyme (ACE)inhibitors is associated with substantial reductions incardiovascular mortality and morbidity among patients
with impaired myocardial function.1 2 The HOPE (heart
outcomes prevention evaluation) study3 has extended our
knowledge of the benefits of ACE inhibition in people who are
at coronary risk but have normal left ventricular function,
with reductions in mortality, myocardial infarction, cardiac
arrest, and heart failure. A recent meta-analysis has also con-
firmed that a substantial reduction in sudden cardiac deaths
occurs in patients treated with an ACE inhibitor early after
myocardial infarction.4 These beneficial effects are inad-
equately explained by the simple hypotensive and natriuretic
effects of systemic inhibition of the renin–angiotensin
system.3 5 It is now thought likely that an anti-inflammatory
action is involved.6
Local (myocardial) or systemic inflammatory processes
could play key roles in the progression of heart failure,7–9 while
local (coronary plaque) or systemic inflammation could medi-
ate atheromatous plaque growth10 and initiate unstable plaque
events.11 It is thought that the pro-inflammatory cytokine
interleukin 6 (IL-6) plays a central role in this. Thus IL-6 con-
centrations are raised in patients with heart failure12 and
indeed may play a causative role in driving heart failure by
stimulating cardiomyocyte apoptosis,8 while IL-6 induced
endothelial activation13 14 together with vascular smooth mus-
cle cell proliferation15 and migration16 may underlie the
atherogenic process.17
Raised systemic concentrations of IL-6 are thus associated
with both the development and the progression of heart
failure.12 18 19 They are also related to the development of
coronary vascular disease,20 21 as well as the transition to
plaque instability.11 Raised concentrations of IL-6 are also cor-
related with mortality in elderly people.22 23 Atherosclerosis is
itself a chronic low grade inflammatory condition character-
ised by activation of the acute phase response,24 and thus local
plaque IL-6 expression may exert important effects. Both vas-
cular smooth muscle cells and inflammatory cells such as
macrophages are key components of the atherosclerotic
plaque,25 26 in which a high tissue ACE expression increases
further upon inflammatory stimulation.27 Concomitant in-
creases in plaque angiotensin II expression28 may drive IL-6
expression. IL-6 is co-localised with ACE within atheroscle-
rotic plaques,29 30 suggesting a possible local role of inflamma-
tion in the initiation and progression of atherosclerosis.17
Plaque ACE is thus considered an important therapeutic
target in its own right.27 It has thus been postulated that the
therapeutic benefits of ACE inhibition may be partly mediated
through an anti-inflammatory action, and specifically through
reductions in local or systemic IL-6 expression.31
The acute phase response following coronary artery bypass
graft surgery (CABG) is associated with the induction and
release of cytokines, including IL-6,32–34 and affords investiga-
tors a useful opportunity to study the impact of various factors
on the acute phase response. However, to date the impact of
ACE inhibitors on post-CABG IL-6 response has not been
investigated. We have thus used this model to perform an
observational study exploring the hypothesis that ACE inhibi-
tion is associated with a reduction in the IL-6 response to
acute inflammatory stimuli.
METHODS
Subjects were drawn from the coronary artery surgery
inflammation study (CASIS). Briefly, all patients undergoing
elective first time CABG at the Middlesex Hospital, London,
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Abbreviations: ACE, angiotensin converting enzyme; CABG, coronary
artery bypass graft; CASIS, coronary artery surgery inflammation study;
HOPE, heart outcomes prevention evaluation study; IL-6, interleukin 6
See end of article for
authors’ affiliations
. . . . . . . . . . . . . . . . . . . . . . .
Correspondence to:
Dr D J Brull, UCL Centre for
Cardiovascular Genetics,
3rd Floor, Rayne Institute,
5 University Street, London
WC1E 6JJ, UK;
d.brull@ucl.ac.uk
Accepted
5 November 2001
. . . . . . . . . . . . . . . . . . . . . . .
252
www.heartjnl.com
UK, between October 1999 and September 2000 were invited
to participate. The study had hospital ethics committee
approval, and all patients gave written informed consent.
Subjects undergoing additional surgical procedures (such
as valvar surgery or aneurysmectomy) were excluded.
All patients were taking aspirin 75 mg/day, and ceased tak-
ing this 10 days before surgery. Other drugs were withheld on
the morning of surgery. ACE inhibitor treatment was given as
usual the night before surgery. No patient had clinical
evidence of active inflammatory or immunomodulatory
disease (such as acute coronary syndromes, malignancy,
intercurrent infection, renal failure, or autoimmune disease)
at recruitment, nor were any receiving anti-inflammatory
agents. Similarly, before analysis all data were excluded from
those subjects who experienced significant postoperative
complications, even if these were only apparent after the six
hour sample time point, as IL-6 rises within hours of an
inflammatory stimulus. Study exclusion criteria thus included
infections requiring antibiotic treatment, prolonged respira-
tory support, circulatory support, or renal failure requiring
haemofiltration.
Surgical procedure
CABG was performed through a midline sternotomy by one of
four consultant surgical staff, with subsequent hypothermic
cardiopulmonary bypass employing right atrial and ascending
aortic cannulation. Myocardial protection was maintained by
intermittent cold cross clamp fibrillation, and heparin
anticoagulation was reversed postoperatively by protamine
sulfate.
A 4.5 ml citrated blood sample was drawn before surgery
(with the patient supine and resting) and again six hours after
cardiopulmonary bypass. Venous blood was immediately cen-
trifuged (at 3500 g for 10 minutes), and the plasma was sepa-
rated and stored at −20°C until analysis. IL-6 concentrations
were measured by enzyme linked immunosorbent assay (R&D
Systems, Abingdon, UK) by staff blind to all subject data.
Interassay and intra-assay coefficients of variation were 5%
and 3%, respectively, and assay sensitivity was < 0.70 pg/ml).
Statistical analysis
All data were analysed using SPSS for Windows version 9
(SPSS Inc, Chicago, Illinois, USA).We analysed raw data when
they were normally distributed. However, the IL-6 values were
skewed, so they were normalised by log transformation (the
data shown represent geometric means and standard devia-
tions). The effect of ACE inhibitor treatment on IL-6 was
assessed by analysis of variance and Student’s t test for
unpaired data. One way analysis of covariance was performed
using age, sex, smoking, diabetic status, left ventricular
ejection fraction, statin treatment, duration of operation, and
cardiopulmonary bypass and aortic cross clamp times as cov-
ariates. Following backwards stepwise linear regression mod-
elling, only variables that had a significant effect on IL-6 con-
centrations were included in the final model. Pearson’s
correlation coefficient was used to test the relation between
IL-6 concentrations and baseline clinical and surgical vari-
ables. The study was powered to detect a 10% difference in
post-CABG IL-6 with 80% power at p < 0.05.
RESULTS
Of 269 elective CABG cases, 172 who fulfilled the inclusion
criteria were randomly approached (depending on investiga-
tor availability), and of these 161 chose to participate. At
enrolment, 41 (25%) were receiving ACE inhibitor treatment:
11 (27%) were on lisinopril, 10 (24%) on ramipril, six (15%) on
enalapril, six (15%) on perindopril, four (10%) on captopril,
and four (10%) were taking other agents. In all, 111 subjects
(67%) were receiving statin treatment. Twenty one patients
experienced confounding postoperative complications and
were thus excluded, according to protocol. This left a final
study group of 140 subjects, including 33 (24%) receiving ACE
inhibitors.
Clinical and operative characteristics (table 1) were largely
independent of ACE inhibitor treatment, although body mass
index was slightly lower. As anticipated, a past medical history
of diabetes or hypertension was more common in ACE inhibi-
tor treated patients. Similarly, a higher proportion of subjects
receiving ACE inhibitors had a left ventricular ejection
fraction below 50% (18/33 v 29/107, p < 0.01).
The correlation between baseline and post-CABG IL-6
values and the major clinical and surgical variables is shown
in table 2. While both baseline and post-CABG IL-6
concentrations were lower in non-diabetic patients, men, and
Table 1 Patient baseline characteristics and operative details
Variable
ACE inhibitor
treatment (n=33)
No ACE inhibitor
treatment (n=107) p Value
Baseline characteristics
Men 27 82
Women 6 25
Age (years) 64 (2) 63 (1) 0.73
Body mass index (kg/m2) 26.5 (0.4) 28.4 (0.7) 0.04
Current smoker 4 (13%) 20 (19%) 0.29
Treated hypertension 18 (55%) 33 (31%) 0.01
Diabetes mellitus 10 (30%) 18 (17%) 0.08
Family history of coronary artery disease 15 (46%) 54 (51%) 0.38
Total cholesterol (mmol/l) 4.8 (0.2) 4.9 (0.1) 0.74
Low density lipoprotein (mmol/l) 2.5 (0.2) 2.6 (0.1) 0.48
High density lipoprotein (mmol/l) 1.4 (0.1) 1.3 (0.1) 0.52
Canadian Cardiovascular Society class 2.6 (0.2) 2.2 (0.1) 0.11
New York Heart Association class 1.8 (0.1) 1.8 (0.1) 0.75
Operative details
Mean number of grafts 2.8 (0.1) 2.8 (0.1) 0.75
Operation duration (minutes) 190 (8) 195 (3) 0.49
Cardiopulmonary bypass time (minutes) 63 (3) 66 (2) 0.31
Aortic cross clamp time (minutes) 34 (3) 32 (1) 0.58
Length of ventilation (hours) 9.3 (0.9) 10.3 (0.4) 0.24
Length of stay in intensive care unit (days) 2.3 (0.5) 2.3 (0.2) 0.85
Length of postoperative stay (days) 7.0 (1.0) 6.6 (0.4) 0.64
Values are n (%) or mean (SEM).
ACE, angiotensin converting enzyme.
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non-smokers, none of these factors was associated with a sig-
nificant effect on IL-6 concentrations; however, post-CABG
IL-6 concentrations were lower in patients receiving statin
treatment (p = 0.029).
The effect of ACE inhibitor treatment on IL-6 concentra-
tions is shown in fig 1.A trend towards lower preoperative IL-6
concentrations among patients receiving ACE inhibitors
(mean (SD), 3.7 (0.1) v 4.3 (0.1) pg/ml, p = 0.12) became less
strong after multivariate analysis. Among the group as a
whole, surgery was associated with a significant increase in
IL-6 concentrations (mean rise, 177 (12) pg/ml, p < 0.0005 by
paired t test). However, this response was significantly blunted
among ACE inhibitor treated patients: median increases in
IL-6 concentrations were 117 pg/ml in treated patients and
193 pg/ml in non-treated patients (Kruskal–Wallis, p = 0.02),
with peak postoperative IL-6 concentrations lower among the
33 patients receiving ACE inhibitors than in the 107 untreated
subjects (142 (19) v 196 (13) pg/ml, p = 0.02). The effect of
ACE inhibitor treatment on post-CABG IL-6 concentrations
remained significant after multivariate analysis (analysis of
covariance, p = 0.018).
DISCUSSION
While the anti-inflammatory role of ACE inhibitors has been
reported previously in vitro,35 36 this study suggests for the first
time that ACE inhibitor treatment is also associated with a
reduction in IL-6 response to coronary artery bypass surgery.
Although observational in nature and not derived from a ran-
domised double blind control study, these data have important
therapeutic implications in at least three fields.
Firstly, the pronounced inflammatory response to CABG is
implicated in the pathogenesis of subsequent hyperdynamic
circulatory instability, delayed myocardial recovery, and organ
dysfunction.33 37 More specifically, prolonged increases of
circulating IL-6 are also associated with increased morbidity
and mortality after cardiac operations.38 It has already been
shown that ACE inhibition may improve outcome in patients
undergoing CABG,39 although a mechanistic explanation for
this observation remains elusive. Our data would support the
suggestion that inherent anti-inflammatory properties of ACE
inhibitor drugs may be responsible.35 However, as the study
was designed only to include subjects with an uncomplicated
postoperative course, it is unsurprising that there was no sig-
nificant difference in the length of hospital stay between those
patients who did or did not receive an ACE inhibitor.
Secondly, there is evidence of cross signalling between the
renin–angiotensin system and IL-6, so the former may
contribute to the pathogenesis of atherosclerosis. Angiotensin
II stimulates IL-6 production by smooth muscle cells, an effect
that can be inhibited by captopril and ramiprilat.36 Steady state
mRNA for IL-6 can also be augmented after stimulation with
angiotensin II, suggesting regulation of angiotensin induced
IL-6 release at the pretranslational level.36 Moreover, angio-
tensin II can also activate the pro-inflammatory transcription
factor nuclear factor κB, which is necessary for transcription
of most cytokine genes, including IL-6.40 Thus it is likely that
angiotensin can elicit an inflammatory response in human
vascular smooth muscle cells by stimulating cytokine produc-
tion and the activation of nuclear factor κB.36 Our data would
support an anti-inflammatory role for ACE inhibition in
reducing vascular event rates in those at risk.3
Finally, the dramatic benefit of ACE inhibition in patients
with heart failure remains to be explained, although our data
once again support a potential anti-inflammatory role in
mediating those effects.41
It remains possible, of course, that it is not the ACE inhibi-
tion on its own that is associated with a reduced IL-6 response,
but the condition that led to such treatment in the first place.
However, we think that unlikely.42 If anything, the inflamma-
tory response to surgery might be expected to be greater
among patients with pre-existing cardiac dysfunction or
diabetes.43 In any event, with the increasing indications for
ACE inhibitor treatment (hypertension, diabetes,44 coronary
artery disease,3 and cardiac dysfunction1 2), there are ethical
concerns about performing a randomised controlled trial of
ACE inhibition in patients selected for coronary surgery.44
Clearly further studies are required, both in vitro, to investi-
gate the effect of ACE inhibitor on IL-6 production using
preparations of cells implicated in IL-6 synthesis (such as
macrophages, fibroblasts, and endothelial cells), and in vivo, to
explore the effect of ACE inhibition on the IL-6 response to
other types and grades of inflammatory stimulus—for exam-
ple, following acute coronary syndromes or coronary interven-
tion. Any such studies need to be both randomised and double
blind in design.Nonetheless, these data are supportive of an in
vivo anti-inflammatory effect of ACE inhibition in humans.
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Table 2 Correlation between IL-6 concentrations
and clinical variables
Variable Preoperative IL-6 Postoperative IL-6
Age r=0.05 (p=0.57) r=−0.19 (p=0.02)
Body mass index r=0.22 (p=0.04) r=0.15 (p=0.15)
Ejection fraction r=−0.12 (p=0.17) r=−0.16 (p=0.08)
Aortic cross clamp time – r=0.08 (p=0.41)
Cardiopulmonary bypass
time
– r=0.14 (p=0.11)
Total duration of surgery – r=0.23 (p=0.01)
Figure 1 Effect of ACE inhibitor treatment on post-coronary artery
bypass graft IL-6.
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